ExpiresJune 10, 2021
Oregon Health & Science University School of Medicine
Statistics from 2009-2013 place mortality from HCV 81% higher in Oregon than in the United States as a whole. There still exists a gap both nationally and in Oregon in screening rates for Hepatitis C with a further gap in those diagnosed with Hepatitis C who have access to receive specialist liver care. Prior HCV ECHO programs from both University New Mexico and VA systems have demonstrated expanded capacity for care by local providers equivalent to that which patients would receive from a liver specialist. (Beste et al, 2017; Arora et al, 2010)
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
The overall course goal is to for participating primary care teams to develop a population health-based approach to hepatitis C treatment, as a means to elimination.
Participants will be able to develop and sustain systems, protocols, and policies to support hepatitis C treatment in the primary care setting
Understand the populations most at risk for contracting hepatitis C
Demonstrate increased competence in the diagnosis/identification of cirrhosis and understanding of when to refer
Identify appropriate hepatitis C treatment candidates and safe treatment with new DAA medications.
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills
CME Credit Type
AMA PRA Category 1 Credit
Inpatient, Outpatient, Rural, Urban, VA/Military